Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Marksans Pharma Ltd. Board/Management Information 2025

Mar 31, 2025

62142_rns_2025-03-31_a8700d61-5714-4192-adfd-886922b057d7.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

==> picture [46 x 46] intentionally omitted <==

==> picture [87 x 19] intentionally omitted <==

==> picture [112 x 19] intentionally omitted <==

March 31, 2025

BSE Limited National Stock Exchange of India Limited Corporate Relation Department Listing Department Phiroze Jeejeeboi Towers, Exchange Plaza, C-1, Block-G, Dalal Street, Bandra-Kurla Complex, Mumbai - 400001. Bandra (East), Mumbai - 400051. Scrip Code: 524404 Symbol: MARKSANS

Sub: Intimation of Completion of Tenure of Mr. Seetharama Raju Buddharaju, Independent Director of the Company, under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we would like to inform you that the tenure of Mr. Seetharama Raju Buddharaju (DIN: 03630668), Independent Director of the Company, has come to an end on March 31, 2025 and consequently, ceased to be the Independent Director of the Company and Member of various Committees of the Board with effect from end of the day on March 31, 2025. The Board of Directors of the Company placed on record their deep appreciation for the contributions made by Mr. Seetharama Raju Buddharaju during his association with the Company over the years.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 are mentioned below as Annexure-A .

You are requested to kindly take the same on your records.

Thanking you,

Yours faithfully, For Marksans Pharma Limited

H Digitally signed by H PANIGRAHI PANIGRAHI Date: 2025.03.31 15:38:36 +05'30'

Harshavardhan Panigrahi Company Secretary & Compliance Officer

==> picture [5 x 69] intentionally omitted <==

==> picture [93 x 16] intentionally omitted <==

==> picture [73 x 16] intentionally omitted <==

==> picture [432 x 34] intentionally omitted <==

Annexure-A

==> picture [46 x 46] intentionally omitted <==

==> picture [87 x 19] intentionally omitted <==

==> picture [112 x 19] intentionally omitted <==

Details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023.

Sr. No. Particular Details
1. Reason for change viz.appointment, re-appointment,resignation,removal,deathor otherwise Mr. Seetharama Raju Buddharaju ceased to be anIndependent Director of the Company andMember of various Committees of the Board onMarch 31, 2025 upon completion of his tenure asIndependent Director on March 31, 2025.
2. Dateofappointment/re-~~appointment/~~cessation (as applicable)&term of appointment/re-appointment w.e.f. end of the day on March 31, 2025
3. Brief profile (in case of appointment) Not Applicable
4. Disclosure of relationships between
directors (in case of appointment of a Not Applicable
director)

==> picture [5 x 69] intentionally omitted <==

==> picture [93 x 16] intentionally omitted <==

==> picture [73 x 16] intentionally omitted <==

==> picture [432 x 34] intentionally omitted <==